Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs

Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan Africa, artemether–lumefantrine remains a first-line therapy even as reduced susceptibility and treatment failures have been reported, including in returning travelers. Public health programs therefore depend on reliable molecular markers to detect resistance early. New findings identify a rapidly spreading group of parasite mutations in Uganda associated with decreased susceptibility to multiple frontline antimalarial drugs.

Researchers at Brown University led a whole-genome analysis of P. falciparum from blood samples collected from hundreds of infected patients in Uganda to identify genetic factors associated with reduced drug susceptibility. The study identified polymorphisms in the phosphoinositide-binding protein (PX1) gene and a linked set of variants, including three specific mutations and two deletions, associated with decreased susceptibility to artemisinin and lumefantrine, as well as mefloquine. The broader genomic signal spans a region containing 69 genes, with PX1 located near another gene product previously linked to moderate artemisinin resistance.

Using parasite whole‑genome sequencing as a surveillance tool, the investigators showed that the newly identified variants are spreading rapidly in Uganda. The analysis connects, for the first time, a gene mutation with reduced susceptibility to multiple agents used together in combination therapy. As of 2026, a longer artemether–lumefantrine course has been recommended for some travelers after standard dosing failures, underscoring the diagnostic and therapeutic stakes for laboratories monitoring treatment response.

The researchers emphasize that the PX1‑linked marker can be incorporated into ongoing molecular surveillance to track the emergence and dissemination of decreased susceptibility to frontline regimens. They note that the current evidence derives from laboratory testing of parasites collected from patients, and that clinical outcome studies of artemisinin‑based combination therapies are a priority. The findings were published in Nature Medicine on August 17, 2026, and involved collaborators at the Infectious Disease Research Collaboration (Uganda), Johns Hopkins University, University of California, San Francisco, University of North Carolina at Chapel Hill, and University of Notre Dame.

“It’s very concerning that these new mutations are spreading so rapidly—it tells us they are important to the parasite’s survival. Malaria still is a major killer, particularly in sub-Saharan Africa. As drug resistance continues to emerge, we worry it will undermine control of its spread and result in even more deaths for a large number of people there and beyond,” said Dr. Jeffrey Bailey, an associate professor of translational research and of pathology and laboratory medicine at Brown University.

“We didn’t have any validated molecular marker of lumefantrine resistance—we knew that there was a gene involved in partial resistance to artemisinin but couldn’t explain changes observed for lumefantrine. Our work identifies a molecular marker that could be used by surveillance studies to track the emergence and spread of reduced susceptibility to frontline malaria treatments across Africa. That’s a very important tool for public health,” said Karamoko Niaré, an adjunct assistant professor of pathology and laboratory medicine at Brown.

Related Links
Brown University